Treatment of Perianal FIstulas in Crohn*s Disease: Surgical closure vs Anti-TNF - PISA II-trial

Academisch Medisch Centrum0 个研究点目标入组 180 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- >= 18 years;- Written informed consent;- High tract (intersphincteric, transsphincteric, suprasphincteric) perianal fistula located in the upper two-thirds of the external sphincter ;- Fistula with one internal opening (based on MRI imaging). The number of external fistulas does not have to be taken into account;- Both new fistulas or recurrent active fistula (defined as any producing fistula)

•- Proctitis (defined as any active mucosal inflammation or ulcer > 5mm in the rectum);- Anorectal stenosis (defined as the impossibility to introduce a proctoscope);- Submucosal fistulas & low intersphincteric fistulas (lower one-third of external sphincter);- Rectovaginal fistula;- Multiple internal openings;- Use of Anti-TNF medication for more than 3 months;- Previous Anti-TNF medication without any effect on perianal fistulas;- Previously demonstrated allergy for anti-TNF medication. If this allergy only concerns the chimeric monoclonal mouse-antibody infliximab, the patient could be randomised for adalumimab;- Patients with a stoma;- Immunocompromised patients with a contra-indication for anti-TNF ;- Life expectancy < 2 years;- The inability of reading/understanding and filling in the questionnaires;- Dementia or altered mental status that would prohibit the understanding and giving of informed

发起方